Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph−) B-cell precursor (BCP) acute lymphoblastic leuk...
Guardado en:
Autores principales: | Hagop M. Kantarjian, Gerhard Zugmaier, Monika Brüggemann, Brent L. Wood, Heinz A. Horst, Yi Zeng, Giovanni Martinelli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c231d049e90a4489be5d68650cd3c8ec |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
por: Franquiz MJ, et al.
Publicado: (2020) -
Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
por: Sigmund AM, et al.
Publicado: (2020) -
Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Fatih M. Uckun, et al.
Publicado: (2021) -
Profound leukemia cutis in a patient with relapsed T-cell acute lymphoblastic leukemia
por: Ambika Nohria, BA, et al.
Publicado: (2021) -
Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma—A Report from the ALL-REZ Study Group
por: Andrej Lissat, et al.
Publicado: (2021)